#Denmark #Dravet Syndrome #Lundbeck #bexicaserin #Valby

Lundbeck's DEEp SEA Trial: A Milestone in Dravet Syndrome Research

On September 15, 2026, H. Lundbeck A/S announced a pivotal advancement in their ongoing efforts to treat Dravet syndrome—a rare and severe form of epilepsy. The last patient has been randomized in the DEEp SEA trial (NCT06660394), a global Phase III clinical study aimed at evaluating the efficacy, safety, and tolerability of bexicaserin. This marks a noteworthy milestone in the broader Phase III DEEp program, which is committed to addressing the critical needs of individuals affected by this condition.

Understanding Dravet Syndrome

Dravet syndrome is distinguished as a developmental and epileptic encephalopathy (DEE) and typically manifests in early childhood. It is characterized by treatment-resistant seizures and poses a significant challenge for those living with the condition. Current estimates indicate that DEEs include over ten syndromes, with Dravet syndrome being one of the most limiting in terms of treatment options available. The urgency for innovative therapies that can effectively manage these seizures is paramount, making the DEEp SEA trial particularly vital.

Trial Overview

The DEEp SEA trial centers on the administration of bexicaserin, a novel investigational drug. This compound is designed to selectively target the 5-HT2C receptor subtype, potentially reducing adverse effects that may arise from treatments affecting other receptor types. The study involves over 100 participants, ranging from two to 65 years old, and adopts a randomized, double-blind, placebo-controlled methodology to ensure rigorous evaluation of results. Participants who complete the trial may also have the opportunity to transition into a 52-week open-label extension (OLE).

During the study, bexicaserin's effectiveness will primarily be assessed through monitoring the reduction of countable motor seizure frequency. The structured treatment phase includes a three-week titration period followed by a 12-week maintenance period, ensuring that dosing is tailored to participants’ needs.

Commitment to Research

According to Tarek Samad, Executive Vice President and Head of Research Development at Lundbeck, completing the randomization is an essential step in the research aimed at people battling Dravet syndrome. The commitment of participants, their families, and the entire medical community involved in this trial emphasizes a collective effort toward advancing potential treatments for severe epilepsy. Lundbeck expresses deep gratitude to all contributors as the study progresses.

Beyond Dravet syndrome, Lundbeck is also conducting another trial, DEEp OCEAN, which focuses on various DEEs excluding Dravet syndrome. Both trials represent Lundbeck's unwavering dedication to pioneering research that expands treatment horizons for neurodevelopmental disorders.

What Lies Ahead

Although bexicaserin is currently investigational and not yet approved by any regulatory authority worldwide, the study holds promise. The FDA has recognized the potential of bexicaserin by granting it Breakthrough Therapy designation for those aged two and above suffering from seizures linked to DEEs. Similarly, China has also granted this designation, reflecting international confidence in the drug’s potential impact.

As the DEEp SEA trial moves forward, Lundbeck continues to be at the forefront of research targeting complex neurological challenges, highlighting the necessity for inclusive approaches to health equity and comprehensive support for affected families.

In conclusion, the successful randomization of the last patient marks a significant achievement not just for Lundbeck but for the entire Dravet syndrome community. It epitomizes hope for innovative therapies that may one day provide relief to those grappling with the challenges of this debilitating condition.